Adaptive Biotechnologies heads into the final days of June with a telling split: options traders are as bullish as they've been all year, yet insiders have been quietly selling into the rally.
The options market is the loudest signal this week. The put/call ratio has collapsed to 0.14 — near its 52-week low of 0.07 and almost 1.5 standard deviations below its 20-day average of 0.32. Call buying is running at its most aggressive relative to puts in months, a sharp reversal from mid-May when the PCR briefly touched 0.68. That shift roughly tracks the stock's 34% jump over the past month to $17.22, and suggests options participants are leaning hard into the move. The borrow market offers little friction for bears: availability is extraordinarily loose at around 1,337% — meaning there are roughly thirteen shares available for every one already lent out — and cost to borrow sits at just 0.43%, barely above a rounding error. Short interest at 5.5% of the free float is broadly unchanged month-over-month, trimming about 5% on the week without signalling any meaningful squeeze dynamic.
The Street is cautiously constructive but not uniform. Morgan Stanley trimmed its target from $21 to $18 last month, keeping an Equal-Weight rating — effectively acknowledging that the post-Q1 rally had priced in the good news. JPMorgan also cut to $19 from $21 while maintaining Overweight. Meanwhile BTIG today reiterated its Buy with a $22 target, reinforcing a floor in bullish conviction. The mean target across covering analysts sits around $20, roughly 16% above the current price, but the cluster of recent downward revisions after May earnings suggests the Street is becoming more selective about what it's willing to pay for. The company carries a deeply negative P/E, with EV/EBITDA running above 160x — a multiple that has compressed sharply (down more than 40 points over 30 days) as the stock rallied into an improving but still loss-making fundamental picture. EPS momentum factor scores of 16 and 20 over 30 and 90-day windows signal that the earnings revision backdrop remains weak.
The insider picture cuts against the call-buying enthusiasm. Every transaction in the recent record is a sale. The Chief Commercial Officer sold 16,000 shares across two trades in early June at prices between $18 and $19. Before that, the President and COO exited more than 100,000 shares across six days in late April at prices around $14. The CFO also sold in May. Across the past 90 days the net direction in shares is notably skewed toward exits, totalling roughly $8.5 million in aggregate value. These are spread across multiple executives and appear systematic rather than opportunistic — but the pattern of selling into a rising tape is worth watching, particularly given BTIG's reiteration today.
Institutional ownership adds one genuinely notable data point. Viking Global Investors holds 18.7% of the company — a position that, as of the most recent filing, was unchanged. That kind of concentrated anchor ownership limits the free float available to trade, which may partly explain why the stock can move sharply on relatively modest volume changes. Westfield Capital and Wellington Management both added meaningfully to positions in recent months, while Invesco lifted its stake by nearly 1.4 million shares.
The next scheduled catalyst is Q2 earnings on July 31. The prior two quarterly prints both produced negative one-day reactions — down 7.6% after the June 5 event and down 0.5% after the May result, with five-day drifts of -2.7% and -6.0% respectively. The setup going into July 31 is therefore the one to watch: whether the loose borrow market, near-record call positioning, and a fresh reiteration from BTIG can hold the stock above the $16–17 range that has capped it for much of the year, or whether the pattern of post-earnings softness reasserts itself against a backdrop of insider distribution.
See the live data behind this article on ORTEX.
Open ADPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
